Stockreport

Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference [Yahoo! Finance]

Belite Bio, Inc - American Depositary Shares  (BLTE) 
PDF autofluorescence (DDAF) lesions in Stargardt disease by over two years (P=0.0033; structured covariance P Tinlarebant is an oral RBP4 antagonist that aims to lower ret [Read more]